[Clinical studies on doxycycline in the treatment of nongonococcal urethritis by Chlamydia trachomatis].
Twenty-one nongonococcal urethritis patients by Chlamydia trachomatis infection were treated with doxycycline (DOXY, Vibramycin) 200 mg/day orally for 2 weeks. The age of these patients were ranged from 17 to 52. C. trachomatis was eradicated 8(89%) of 9 cases on 3rd day and never reisolated on 7th day after treatment. Ten (83%) of 12 patients on 7th day and any patients on 14th day were not suffered from symptoms after treatment. Urethral discharge was not seen macroscopically, 11 (92%) of 12 patients on 7th day and any patients on 14th day. According to the criteria for urethritis requiring at least 4 WBC per high power field in urethral smear and/or first voided urine, the overall clinical efficacy rate was 44% (4/9) on 3rd day, 83% (10/12) on 7th day and 100% (9/9) on 14th day. No side effects were recognized in any cases. In conclusion, DOXY was thought to be useful and safe drug in the treatment of nongonococcal urethritis by C. trachomatis.
D000293:Adolescent; D000328:Adult; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D004318:Doxycycline / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000302:isolation & purification; D011776:Pyuria / Q000188:drug therapy; D013997:Time Factors; D014526:Urethritis / Q000188:drug therapy*; D014556:Urine / Q000382:microbiology
D004318:Doxycycline